Edwards Lifesciences Corporation $EW Shares Acquired by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund increased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 32.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 67,115 shares of the medical research company’s stock after purchasing an additional 16,429 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Edwards Lifesciences were worth $5,220,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of EW. Econ Financial Services Corp purchased a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $889,000. Randolph Co Inc acquired a new position in Edwards Lifesciences during the second quarter worth about $301,000. OMERS ADMINISTRATION Corp increased its holdings in Edwards Lifesciences by 97.3% in the second quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock valued at $3,481,000 after buying an additional 21,950 shares in the last quarter. Arkadios Wealth Advisors acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at approximately $300,000. Finally, Pacific Capital Partners Ltd purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter worth approximately $1,760,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Up 0.7%

Shares of EW stock opened at $85.14 on Friday. The company has a market capitalization of $49.41 billion, a price-to-earnings ratio of 36.70, a PEG ratio of 3.46 and a beta of 0.95. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The firm has a 50-day moving average price of $85.06 and a 200 day moving average price of $80.35. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.08. The company had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The firm’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same period last year, the company earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

EW has been the subject of several research analyst reports. Wall Street Zen downgraded Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. UBS Group set a $92.00 target price on Edwards Lifesciences in a report on Friday, December 5th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $108.00 price target on shares of Edwards Lifesciences in a research note on Friday. Canaccord Genuity Group set a $87.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Wednesday, December 17th. Finally, JPMorgan Chase & Co. upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $90.00 to $100.00 in a research report on Thursday, December 18th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.57.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,885,571.40. The trade was a 4.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 7,700 shares of the business’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total value of $650,419.00. Following the completion of the transaction, the chief financial officer owned 39,898 shares of the company’s stock, valued at $3,370,184.06. This trade represents a 16.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 57,824 shares of company stock worth $4,863,323. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.